EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS

Jessica R Allegretti iD, Paul Feuerstadt iD, Whitfield L Knapple, Robert Orenstein, Philippe Pinton, Alexander Sheh, Sahil Khanna

Inflammatory Bowel Diseases · 01.08.2025 · 31 (8) · 2112-2122

DOI: 10.1093/ibd/izae291 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 25.01.2025. Verfasst von Jessica R Allegretti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections, Fecal Microbiota Transplantation, Feces. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ferring Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fecal microbiota, live-jslm (RBL; REBYOTA®), is the first single-dose, broad consortia, microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care antimicrobials. Inflammatory bowel disease (IBD) is a common risk factor for rCDI, yet patients with IBD are often excluded from prospective trials. This subgroup analysis of PUNCH CD3-OLS (NCT03931941) evaluated the safety and efficacy of RBL in participants with rCDI and IBD.

Methods

Participants with IBD (ulcerative colitis [UC], Crohn’s disease [CD], or unspecified) who had rCDI were included. Treatment-emergent adverse event (TEAE) data were collected for up to 6 months following RBL administration. Efficacy outcomes included treatment success at 8 weeks and sustained clinical response at 6 months.

Results

Overall, 793 participants were enrolled, and 697 received RBL; 74 had IBD (UC: n = 45; CD: n = 25; unspecified IBD: n = 4). TEAEs within 8 weeks of administration were reported by 45.9% and 47.5% of participants with and without IBD, respectively; most were mild or moderate gastrointestinal symptoms. Serious TEAEs within 8 weeks of administration were reported by 1.4% and 4.2% of participants with and without IBD, respectively. The treatment success rate at 8 weeks was 78.9%, and the sustained clinical response rate at 6 months was 91.1% in participants with IBD, similar to rates in participants without IBD (73.2% and 91.0%, respectively).

Conclusions

The results of this subgroup analysis of PUNCH CD3-OLS suggest RBL is safe and efficacious in patients with IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridioides difficileClostridium InfectionsFecal Microbiota TransplantationFecesInflammatory Bowel DiseasesAdultFemaleHumansMaleMiddle AgedYoung AdultGastrointestinal MicrobiomeProspective StudiesRecurrenceSecondary PreventionTreatment Outcome

Stichwörter der Autor:innen

C. difficileCrohn’s diseaseRBX2660microbiota restorationulcerative colitis

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.
  • Division of Digestive Disease, Yale University School of Medicine, New Haven, CT, USA.
  • PACT-Gastroenterology Center, Hamden, CT, USA.
  • Arkansas Gastroenterology, North Little Rock, AR, USA.
  • Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA.
  • Global Research and Medical, Ferring Pharmaceuticals A/S, Kastrup, Denmark.

ORCID-Profile: Jessica R Allegretti, Paul Feuerstadt

Förderung

  • Ferring Pharmaceuticals

Zitieren

APA

Allegretti, J. R., Feuerstadt, P., Knapple, W. L., Orenstein, R., Pinton, P., Sheh, A., & Khanna, S. (2025). Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS. Inflammatory Bowel Diseases, 31(8), 2112-2122. https://doi.org/10.1093/ibd/izae291

Vancouver

Allegretti JR, Feuerstadt P, Knapple WL, Orenstein R, Pinton P, Sheh A, et al. Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS. Inflammatory Bowel Diseases. 2025;31(8):2112-2122. doi:10.1093/ibd/izae291

BibTeX
@article{Allegretti2025,
  author = {Allegretti, Jessica R and Feuerstadt, Paul and Knapple, Whitfield L and Orenstein, Robert and Pinton, Philippe and Sheh, Alexander and Khanna, Sahil},
  title = {Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {8},
  pages = {2112--2122},
  doi = {10.1093/ibd/izae291}
}
Kostenlos starten →